Edwards Lifesciences Corporation (EW) Operating Margin
- Operating margin · 12 months: Value 22.25%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | 22.25% | Operating income / revenue. Period ending 2026-06-30. $1.45B ÷ $6.51B × 100 ≈ 22.25% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | 1.45B USD | Operating Income (Loss) |
| Revenue | 6.51B USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 1.44B USD | Cost of Goods and Services Sold |
| Research and development | 1.09B USD | Research and Development Expense |
| Selling, general and administration | 2.20B USD | Selling, General and Administrative Expense |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.45B | $6.51B | $1.44B | $1.09B | $2.20B | 22.25% |
| 2026-03-31 | $1.35B | $6.30B | $1.40B | $1.09B | $2.14B | 21.37% |
| 2025-12-31 | $1.26B | $6.07B | $1.33B | $1.08B | $2.09B | 20.84% |
| 2025-09-30 | $1.43B | $5.88B | $1.28B | $1.08B | $1.97B | 24.23% |
| 2025-06-30 | $1.47B | $5.69B | $1.20B | $1.06B | $1.88B | 25.84% |
| 2025-03-31 | $1.42B | $5.52B | $1.13B | $1.05B | $1.83B | 25.80% |
| 2024-12-31 | $1.38B | $5.44B | $1.12B | $1.05B | $1.79B | 25.35% |
| 2024-09-30 | $1.64B | $6.31B | $1.48B | $1.13B | $1.96B | 25.94% |
| 2024-06-30 | $1.65B | $6.20B | $1.47B | $1.12B | $1.92B | 26.64% |
| 2024-03-31 | $1.53B | $6.14B | $1.44B | $1.10B | $1.88B | 24.96% |
| 2023-12-31 | $1.53B | $6.00B | $1.38B | $1.07B | $1.82B | 25.55% |
| 2023-09-30 | $1.58B | $5.82B | $1.28B | $1.03B | $1.76B | 27.18% |
| 2023-06-30 | $1.57B | $5.66B | $1.18B | $997.30M | $1.69B | 27.68% |
| 2023-03-31 | $1.70B | $5.50B | $1.11B | $977.80M | $1.63B | 30.87% |
| 2022-12-31 | $1.75B | $5.38B | $1.08B | $945.20M | $1.57B | 32.49% |
| 2022-09-30 | $1.68B | $5.36B | $1.13B | $945.80M | $1.58B | 31.23% |
| 2022-06-30 | $1.66B | $5.36B | $1.19B | $950.20M | $1.57B | 31.06% |
| 2022-03-31 | $1.75B | $5.36B | $1.25B | $924.70M | $1.53B | 32.58% |
| 2021-12-31 | $1.69B | $5.23B | $1.25B | $903.10M | $1.49B | 32.30% |
| 2021-09-30 | $1.67B | $5.09B | $1.24B | $866.00M | $1.41B | 32.73% |
| 2021-06-30 | $1.63B | $4.93B | $1.21B | $823.50M | $1.35B | 33.19% |
| 2021-03-31 | $923.00M | $4.47B | $1.11B | $780.30M | $1.25B | 20.63% |
| 2020-12-31 | $897.60M | $4.39B | $1.08B | $760.70M | $1.23B | 20.46% |
| 2020-09-30 | $857.00M | $4.37B | $1.07B | $758.90M | $1.24B | 19.62% |
| 2020-06-30 | $793.50M | $4.32B | $1.08B | $758.90M | $1.24B | 18.36% |
| 2020-03-31 | $1.23B | $4.48B | $1.15B | $768.70M | $1.27B | 27.45% |
| 2019-12-31 | $1.15B | $4.35B | $1.11B | $752.70M | $1.24B | 26.38% |
| 2019-09-30 | $830.70M | $4.15B | $1.06B | $721.90M | $1.18B | 20.01% |
| 2019-06-30 | $785.30M | $3.96B | $995.40M | $688.20M | $1.15B | 19.81% |
| 2019-03-31 | $769.90M | $3.82B | $937.60M | $650.40M | $1.11B | 20.15% |
| 2018-12-31 | $748.20M | $3.72B | $939.40M | $622.20M | $1.09B | 20.10% |
| 2018-09-30 | (m) | $3.63B | $940.00M | $605.70M | $1.07B | (m) |
| 2018-06-30 | (m) | $3.55B | $928.40M | $586.80M | $1.04B | (m) |
| 2018-03-31 | (m) | $3.45B | $893.30M | $567.10M | $1.01B | (m) |
| 2017-12-31 | (m) | $3.44B | $875.30M | $552.60M | $984.70M | (m) |
| 2017-09-30 | (m) | $3.31B | $853.20M | $522.00M | $951.60M | (m) |
| 2017-06-30 | (m) | $3.23B | $841.30M | $492.10M | $936.60M | (m) |
| 2017-03-31 | (m) | $3.15B | $832.70M | $470.20M | $921.60M | (m) |
| 2016-12-31 | (m) | $2.96B | $797.40M | $443.30M | $904.70M | (m) |
| 2016-09-30 | (m) | $2.87B | $760.10M | $426.60M | $893.40M | (m) |
| 2016-06-30 | (m) | $2.74B | $705.40M | $414.50M | $875.80M | (m) |
| 2016-03-31 | (m) | $2.60B | $661.50M | $399.10M | $860.90M | (m) |
| 2015-12-31 | (m) | $2.49B | $617.20M | $383.10M | $850.70M | (m) |
| 2015-09-30 | (m) | $2.44B | $601.70M | $368.90M | $851.50M | (m) |
| 2015-06-30 | (m) | $2.43B | $623.10M | $355.50M | $861.70M | (m) |
| 2015-03-31 | (m) | $2.39B | $615.70M | $347.10M | $863.30M | (m) |
| 2014-12-31 | (m) | $2.32B | $625.60M | $346.50M | $858.00M | (m) |
| 2014-09-30 | (m) | $2.24B | $614.80M | $341.10M | $833.70M | (m) |
| 2014-06-30 | (m) | $2.13B | $574.90M | $337.60M | $789.30M | (m) |
| 2014-03-31 | (m) | $2.07B | $547.30M | $329.00M | $760.40M | (m) |
| 2013-12-31 | (m) | $2.05B | $522.40M | $323.00M | $745.60M | (m) |
| 2013-09-30 | (m) | $2.02B | $502.70M | $319.30M | $733.00M | (m) |
| 2013-06-30 | (m) | $1.97B | $484.70M | $309.00M | $720.30M | (m) |
| 2013-03-31 | (m) | $1.94B | $489.50M | $302.50M | $713.30M | (m) |
| 2012-12-31 | (m) | $1.90B | $494.60M | $291.30M | $705.30M | (m) |
| 2012-09-30 | (m) | $1.82B | $488.40M | $277.10M | $690.80M | (m) |
| 2012-06-30 | (m) | $1.78B | $502.30M | $265.00M | $688.50M | (m) |
| 2012-03-31 | (m) | $1.73B | $500.30M | $255.90M | $669.30M | (m) |
| 2011-12-31 | (m) | $1.68B | $489.80M | $246.30M | $642.40M | (m) |
| 2011-09-30 | (m) | $1.64B | $483.70M | $241.50M | $621.40M | (m) |
| 2011-06-30 | (m) | $1.58B | $453.90M | $232.50M | $588.90M | (m) |
| 2011-03-31 | (m) | $1.51B | $426.50M | $218.20M | $566.30M | (m) |
| 2010-12-31 | (m) | $1.45B | $408.30M | $204.40M | $550.00M | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | $1.35B | (m) | (m) | (m) | (m) |
| 2009-12-31 | (m) | $1.32B | $399.10M | $175.50M | $508.80M | (m) |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $1.24B | $419.60M | $139.20M | $480.60M | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STERIS plc (STE) | Ireland | $20.343B | 25.49 |
| ZIMMER BIOMET HOLDINGS, INC. (ZBH) | United States | $17.103B | 20.66 |
| ALIGN TECHNOLOGY INC (ALGN) | United States | $10.346B | 29.06 |
| MSA Safety Inc (MSA) | United States | $7.023B | 21.47 |
| ESTABLISHMENT LABS HOLDINGS INC. (ESTA) | $1.954B | -65.76 | |
| Cadre Holdings, Inc. (CDRE) | United States | $1.123B | 33.88 |
| Enovis CORP (ENOV) | United States | $1.053B | -1.18 |
| Anteris Technologies Global Corp. (AVR) | United States | $0.746B | |
| Sanara MedTech Inc. (SMTI) | United States | $0.323B | -6.81 |
| Inogen Inc (INGN) | United States | $0.139B | -7.00 |